Morgan Stanley Maintains Overweight on Cytokinetics, Raises Price Target to $71

Benzinga · 12/23/2025 15:15
Morgan Stanley analyst Jeffrey Hung maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $65 to $71.